Monitoring of pp65 antigenaemia test for cytomegalovirus after initiation of highly active antiretroviral therapy.
Miguelez
M
M
Diez
O
O
D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000276:immunology / Q000821:virology*; D000328:Adult; D000956:Antigens, Viral / Q000097:blood* / Q000276:immunology; D018791:CD4 Lymphocyte Count; D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000097:blood / Q000276:immunology / Q000821:virology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000097:blood* / Q000276:immunology / Q000302:isolation & purification; D014763:Viral Matrix Proteins / Q000097:blood* / Q000276:immunology
D000956:Antigens, Viral; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa